Bone, Immunologic, and Virologic Effects of a Antiretroviral Regimen
Status:
Completed
Trial end date:
2014-06-01
Target enrollment:
Participant gender:
Summary
The main purpose of this study was to compare the effects on bones of the following two drug
combinations:
- maraviroc (MVC), emtricitabine (FTC), plus darunavir/ritonavir (DRV/r)
- tenofovir (TDF) plus emtricitabine (FTC) plus darunavir/ritonavir (DRV/r)
Additional study objectives were the following:
- To see how the drug combinations affect the brain and kidneys.
- To see how well the drug combinations lower the HIV viral load.
- To see how safe the drug combinations are, how well people are able to take the study
drug combinations, and how well their immune systems respond to the study drugs.
Phase:
Phase 2
Details
Lead Sponsor:
AIDS Clinical Trials Group
Collaborator:
National Institute of Allergy and Infectious Diseases (NIAID)